Award-Winning PV Technology
Synapse Medicine’s Medication Shield technology was awarded the 2021 Prix Galien, France in the digital health category, and was recently nominated for the 2022 Prix Galien International.
Streamlining Pharmacovigilance with the Medication ShieldThe "Medication Shield" technology manages adverse drug reaction (ADR) signals in real-time by encoding them automatically into a standardized, international terminology (MedDRA) and ranking them by severity. This helps pharmacovigilance teams in their daily management of ADRs reports.
Real-Time Coding of ADEs with MedDRA ClassificationThe Medication Shield's natural language processing (NLP) algorithms extract the terms used when reporting an adverse reaction and find their corresponding term according to MedDRA classification. The Medication Shield then analyzes whether the adverse reaction is expected, its level of severity and its frequency.
The Medication Shield Impact on Pharmacovigilance
Medication Shield AUC Performance (Area Under the Curve) Specificity / Sensitivity
From 40 to 2 minutes
Reduction in time spent per pharmacovigilance report
Seamless Integration with Third-Party Software
The Medication Shield integrates easily with third-party ADE management software. It allows actors involved in pharmacovigilance to benefit from the power of the Medication Shield’s artificial intelligence while continuing to use their everyday software.
Safeguarding the COVID-19 Vaccination Campaign in France
The Medication Shield is also being used as part of the COVID-19 vaccination campaign in France. In partnership with the ANSM*, the integration of the Medication Shield facilitates the daily management of adverse event reports by pharmacovigilance teams.
*Agence Nationale de Sécurité du Médicament et des produits de santé
Scientific Publications on the Medication Shield
Our latest publication on the "Medication Shield" technology, Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions can be found in the August 2021 issue of Clinical Pharmacology & Therapeutics, a leading international scientific journal.
Synapse Medicine, the ANSM (French equivalent to the FDA), the Pharmacology Department of Bordeaux University Hospital, and the Pharmacoepi - Inserm U1219 BPH team of the University of Bordeaux.